Hints and tips:
...T Rowe Price diversifies with Oak Hill deal T Rowe Price is known for several things: strong actively managed fund performance, low staff turnover and successful investments in companies such as Twitter...
...(FT) Coaching v commanding Andrew Hill recounts how industrial group Linde won over sceptical staff in 2017 with a safety drive based on “active listening”....
...Many French cinema owners, who are putting pressure on Cannes to resist Netflix et al, see the streamers’ disruptive attitude as an incursion into their territory....
...As diabetic patients have shared horror stories about not being able to afford insulin, Sanofi and rivals Eli Lilly and Novo Nordisk have come under fire for price increases on the essential medicine....
...The government has vowed to tackle the price of cancer medicines, threatening revenues for multinationals such as Eli Lilly, Roche and Novartis....
...Yasir Al-Rumayyan, the head of the PIF, even joined the company’s board....
...Rival Eli Lilly announced job cuts and a focus on new medicines while AstraZeneca was boosted by good news on its cancer pipeline....
...Lilly Ledbetter, the equal pay advocate whose court case on wage discrimination made it to the Supreme Court and resulted in the Lilly Ledbetter Fair Pay Act in 2009, welcomes the #MeToo movement....
...) Eli Lilly mulls spin-off or sale of animal health business (FastFT) Cargill ramps up animal nutrition business with Diamond V deal (FastFT) Asian buyers tap into ‘pampered pooch’ market (FT) ICE to...
...Additional reporting by James Fontanella-Khan Letter in response to this article: Uber et al are not entitled to ‘own’ anything / From Stephen Swift, London, UK...
...a cheaper “biosimilar” alternative made by Eli Lilly....
...Eli Lilly, the US drugmaker, is due to publish data later this year from a large study of its drug, Solanezumab, which is also designed to slow down Alzheimer’s by clearing the brain of amyloid plaques....
...(FT) High stakes In a few weeks, the world will know whether Sola — a drug that pharma group Eli Lilly has spent many years developing — really does slow Alzheimer’s disease....
...● Heartbreaking news for philanthropists who selflessly invest in big pharma, Eli Lilly has been forced to declare that a potential blockbuster cardiac drug is not the jump start for hearts it hoped for....
...Eli Lilly, up 2.4 per cent, and Sanofi, which added 1.6 per cent....
...John Lechleiter, Eli Lilly’s chief executive, dismisses as “hogwash” the idea that incremental improvements are not worth paying for....
...The latest case, Google v Joffe et al, involves a class action suit stemming from the company’s illicit collection of snippets of information from WiFi networks in homes that its StreetView cars were passing...
...Bernard Munos, a former Eli Lilly executive who has studied 60 years of pharmaceutical innovation, says all big drug groups tried to scale up....
...Of course, he also once hinted to me, years ago, that the future could hold an even cheaper third line, to compete with Uniqlo et al, and that hasn’t happened, so I take this with a grain of salt, but still...
...Eli Lilly & Co., maker of Zyprexa, says the drug’s label guides doctors to weigh the risks and consider therapy as part of the treatment.”...
...Lilly and current chairman of PhRMA, the trade body....
...While the black taffeta evening gowns and sturdy looking peacoats on Karlie Kloss et al shouted winter, the models’ peachy complexions were all spring – try Bobbi Brown’s Sheer Color Cheek Tint in Sheer...
...Its central figure is Eli McCullough, who, as a child, sees his family murdered and is kidnapped by the Comanche. He lives to be 100....
...United States v Apple, Inc et al is more than a US Justice department antitrust action against publishers allegedly colluding on ebook prices....
...The case (now called FCC v. Fox Television Stations et al) was appealed to the US Supreme Court, where it was debated on Tuesday....
International Edition